Journal
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
Volume 45, Issue 3, Pages 598-601Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/21691401.2016.1163717
Keywords
Aptamers; nanoparticles; nano-radiopharmaceuticals; radiopharmaceuticals
Categories
Funding
- National Scientific and Technological Research Council (CNPQ)
- Rio de Janeiro State Research Foundation (FAPERJ)
Ask authors/readers for more resources
The use of monoclonal antibodies and aptamers is growing every single day, as the use of nanoparticle systems. Although most of the products are under investigation, there are a few commercialized products available at the market, for human consume. In this study, we have compared three formulations (aptamer anti-MUC1, monoclonal antibody -Trastuzumab and monoclonal antibodies nanoparticles -PLA/PVA/MMT trastuzumab) to identify their profile as also to understand their behavior into an alive biological system. In this direction the radiolabeling of the products were done and they were all tested in animals (in vivo) in two conditions: healthy rats and breast cancer induced animals. The results showed that the nanoparticle has the better biodistribution profile, followed by the aptamer. We conclude that more studies and a global effort to elucidate the biological behavior of drugs and especially nano-drugs are necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available